Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso-Reference-Cited by-同舟云学术

Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso

Published:2021-07-16 Issue:8 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Beshir Khalid B.¹,Diallo Nouhoum²,Somé Fabrice A.³,Sombie Salif⁴,Zongo Issaka³,Fofana Bakary²,Traore Aliou²,Dama Souleymane²,Bamadio Amadou²,Traore Oumar B.²,Coulibaly Sam A.⁴,Maurice Ouattara S.⁵,Diarra Amidou⁵,Kaboré Jean Moise⁵,Kodio Aly²,Togo Amadou Hamidou²,Dara Niawanlou²,Coulibaly Moctar²,Dao Francois²,Nikiema Frederic³,Compaore Yves D.³,Kabore Naomie T.³,Barry Nouhoun³,Soulama Issiaka⁴,Sagara Issaka²,Sirima Sodiomon B.⁵,Ouédraogo Jean-Bosco³,Djimde Abdoulaye²,Sutherland Colin J.¹^ORCID

Affiliation:

1. Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

2. Malaria Research and Training Centre, Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali

3. Institut de Recherche en Sciences de la Santé Direction Régionale de l’Ouest, Bobo-Dioulasso, Burkina Faso

4. Centre National de Recherche et de Formation sur le Paludisme, Ougadougou, Burkina Faso

5. Groupe de Recherche Action en Santé, Ougadougou, Burkina Faso

Abstract

A recent randomized controlled trial, the WANECAM (West African Network for Clinical Trials of Antimalarial Drugs) trial, conducted at seven centers in West Africa, found that artemether-lumefantrine, artesunate-amodiaquine, pyronaridine-artesunate, and dihydroartemisinin-piperaquine all displayed good efficacy. However, artemether-lumefantrine was associated with a shorter interval between clinical episodes than the other regimens.

Funder

European and Developing Countries Clinical Trials Partnership

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00873-21

Reference43 articles.

1. WHO. 2020. World malaria report 2020: 20 years of global progress and challenges. World Health Organization, Geneva, Switzerland.

2. WHO. 2020. Global database on antimalarial drug efficacy and resistance. https://app.powerbi.com/view?r=eyJrIjoiNmRhYWU4ODgtMDI2NC00ZTA0LWE4Y2ItNjVmOGQ5OTY5MTEyIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9. Accessed 3 February 2021.

3. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial

4. Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether–lumefantrine treatment in Mali

5. Continued Low Efficacy of Artemether-Lumefantrine in Angola in 2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children;Nature Communications;2024-05-07

2. Impact of Drug Exposure on Resistance Selection Following Artemether‐Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda;Clinical Pharmacology & Therapeutics;2022-11-14

3. Parasite clearance dynamics in children hospitalised with severe malaria in the Ho Teaching Hospital, Volta Region, Ghana;Parasite Epidemiology and Control;2022-11

4. Persistence of Residual Submicroscopic P. falciparum Parasitemia following Treatment of Artemether-Lumefantrine in Ethio-Sudan Border, Western Ethiopia;Antimicrobial Agents and Chemotherapy;2022-09-20

5. Malaria Transmission Dynamics in a High-Transmission Setting of Western Kenya and the Inadequate Treatment Response to Artemether-Lumefantrine in an Asymptomatic Population;Clinical Infectious Diseases;2022-06-29